Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Massachusetts General Hospital, f514c9)
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Fecal microbiota transplant (FMT) is an investigational live biotherapeutic product developed by Massachusetts General Hospital for the treatment of Clostridium difficile infection (CDI). The therapy involves transferring fecal matter from a healthy, screened donor to a patient to restore a healthy gut microbiome. [3, 4] The product is prepared as a frozen inoculum, which can be administered via orally-ingested capsules, nasogastric tube, or colonoscopy. [3, 5] Clinical studies have evaluated its safety and efficacy in treating recurrent or refractory CDI, with trials exploring different delivery methods and dosing schedules. [2, 5, 9] The underlying mechanism is the reconstitution of normal gut flora, which helps to suppress the pathogenic C. difficile and resolve the infection and associated diarrhea. [3]
- Other names
- FMTstool transplantfecal bacteriotherapy
Beyond the preview
Go deeper on fecal microbiota transplant (Massachusetts General Hospital, f514c9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Massachusetts General Hospital, f514c9).